Catalent to be Added to S&P 500® Index
SOMERSET, N.J. – September 11, 2020 — Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today welcomed the news that the company is being added to the iconic S&P 500® index published by S&P Dow Jones Indices.
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data, and research, and home to many well-known financial market indicators, including the Dow Jones Industrial Average® as well as the S&P 500.
“This designation is an affirmation of our strategy and the substantial progress we have made in executing it since our IPO in 2014,” commented John Chiminski, Chair and Chief Executive Officer of Catalent. “None of this would have been possible without the passion and dedication of our 14,000 employees, whose commitment to our mission to help people live better, healthier lives has propelled Catalent to where we are today.”
As the supplier of over 70 billion doses of more than 7,000 products, for 1,000+ customers around the world, Catalent is pleased to help represent the healthcare sector in the S&P 500. Catalent now employs 14,000 people, including approximately 2,400 scientists, working on the latest medicines and consumer health products, including more than 50 COVID-19-related vaccine and treatment candidates.
The index change, which will see Catalent move from the S&P MidCap 400®to the S&P 500, will take place on Sept. 21, 2020.
For more information about S&P Dow Jones Indices, please visit >https://www.spglobal.com/spdji.
Notes for Editors
S&P 500® and S&P MidCap 400® are registered trademarks of Standard & Poor’s Financial Services LLC. Catalent® is a registered trademark of R.P. Scherer Technologies, Inc., a wholly owned subsidiary of Catalent, Inc.
Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs 14,000 people, including approximately 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com